United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fremanezumab (unii: pf8k38cg54) (fremanezumab - unii:pf8k38cg54) - ajovy is indicated for the preventive treatment of migraine in adults. ajovy is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ajovy during pregnancy. healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.  risk summary there are no adequate data on the developmental risk associated with the use of ajovy in pregnant women. ajovy has a long half-life [see clinical pharmacology (12.3)] . this should be taken into consideration for women who are pregnant or plan to become pregnant while using ajovy. administration of fremanezumab-vfrm to rats and rabbits during the period of organogenesis or to rats throu

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fremanezumab, quantity: 225 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; histidine; polysorbate 80; disodium edetate; sucrose; water for injections - ajovy is indicated for the preventive treatment of migraine in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fremanezumab, quantity: 225 mg - injection, solution - excipient ingredients: histidine; disodium edetate; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - ajovy is indicated for the preventive treatment of migraine in adults.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - injection - see ingredients - each syringe or pen contains fremanezumab 225,0 mg

European Union - English - EMA (European Medicines Agency)

teva gmbh - fremanezumab - migraine disorders - calcitonin gene-related peptide (cgrp) antagonists - ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Canada - English - Health Canada

teva canada limited - fremanezumab - solution - 225mg - fremanezumab 225mg - calcitonin-gene-related peptide (cgrp) antagonists

Canada - English - Health Canada

teva canada limited - fremanezumab - solution - 225mg - fremanezumab 225mg - calcitonin-gene-related peptide (cgrp) antagonists

Israel - English - Ministry of Health

abic marketing ltd, israel - fremanezumab - solution for injection - fremanezumab 225 mg / 1.5 ml - ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Singapore - English - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - fremanezumab - injection, solution - fremanezumab 225 mg/1.5 ml

Singapore - English - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - fremanezumab - injection, solution - fremanezumab 225 mg/1.5ml